Yahoo Finance

Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease

JERUSALEM, ISRAEL--(Marketwired - Dec 14, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary ...
Yahoo Finance

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms

JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary ...
Investing

Intec Pharma: Bolstering The Case For AP-CDLD

statistic for AP-CDLD between the two trials: it was 5.15 hours in the IN 11 005 trial, but significantly lower under similar fasted conditions (1.70h) in the IN 14 001 trial.
Medindia

Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients

Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for ...
Investing

Intec Pharma: Continued Confidence In AP-CDLD

Recently released data from two PK studies of AP-CDLD showed their formulation had lower peak serum concentrations and a longer half-life, which should lower these side effects. The problem with ...